恒瑞医药在研管线包括已上市创新药的适应症扩展进度、NDA联A、VEGFR、FNBRCA1、ET的MUHER2、EE(S4R-1791± (化/7)HIR1, HER2, HER4联台(2HR-A1311)GARAA联8(R27)PD-1REUIBNEMHAINSCLC)饿8TPDL1N达ROEINE(2t-2H%-B)ER比得)有BRCA12E的HER2MRPARP合 (SHR-A1811)联合(RFOLHNOX)血TPO-RHRE件、HER2用件R8EHREHER2DMRXRimCOK41G合(HRSIEOT)HRIEIS9OLT-2(%4-2=)HRCHHER2uRRSLMAWEAR。其中，恒瑞已上市创新药适应症扩展进度包括NDA联A、VEGFR、FNBRCA1、ET的MUHER2、EE(S4R-1791± (化/7)HIR1, HER2, HER4联台(2HR-A1311)GARAA联8(R27)PD-1REUIBNEMHAINSCLC)饿8TPDL1N达ROEINE(2t-2H%-B)ER比得)有BRCA12E的HER2MRPARP合 (SHR-A1811)联合(RFOLHNOX)血TPO-RHRE件、HER2用件R8EHREHER2DMRXRimCOK41G合(HRSIEOT)HRIEIS9OLT-2(%4-2=)HRCHHER2uRRSLMAWEAR。
